Pharmacological treatment of COPD – New evidence
Authors:
- A.J. FerreiraAFA.J. Ferreira
- C. BárbaraCBC. Bárbara
- on behalf of GI DPOC Interest Group on Chronic Obstructive Pulmonary DiseaseODon behalf of GI DPOC Interest Group on Chronic Obstructive Pulmonary Disease
Open Access
- 28 November 2018
- journal article
- review article
- Published by Taylor & Francis in Pulmonology
- Vol. 25 (2) , 90-96
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is currently the 4th leading cause of death worldwide but is projected to be the 3rd leading cause of death by 2020. In Portugal, the estimated prevalence of COPD in the Lisbon region is 14.2%, and a large proportion of underdiagnosed disease has been detected. In 2016, a Portuguese panel of experts proposed pharmacological treatment approaches to COPD based on the evidence available at the time. However, given that the GOLD 2017 report introduced considerable changes to the 2016 version, and that new evidence has emerged regarding treatment options, these proposals need to be updated. Also, and based on several studies, the concept of Pre-GOLD patients, which has diagnostic, prognostic and therapeutic implications, is introduced, along with a proposed algorithm for the identification and treatment of these patients.Keywords
This publication has 41 references indexed in Scilit:
- The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to DPulmonary Pharmacology & Therapeutics, 2015
- Instability in the COPD Diagnosis upon Repeat Testing Vary with the Definition of COPDPLOS ONE, 2015
- COPD: early diagnosis and treatment to slow disease progressionInternational Journal Of Clinical Practice, 2014
- Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group studyThe Lancet Respiratory Medicine, 2013
- Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group studyThe Lancet Respiratory Medicine, 2013
- Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classificationEuropean Respiratory Journal, 2012
- Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary diseaseThorax, 2012
- Creating scenarios of the impact of copd and their relationship to copd assessment test (CAT™) scoresBMC Pulmonary Medicine, 2011
- Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPDNew England Journal of Medicine, 2011
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2010